Form 4: Vor Biopharma CEO Ang Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Vor Biopharma CEO Robert Ang sold 12,657 shares of common stock on March 1, 2024, to cover tax obligations related to the settlement of restricted stock units.
Summary
- On March 1, 2024, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 12,657 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The shares were sold at a price of $2.27 per share.
- Following the transaction, Ang directly owns 815,480 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: The document is a standard Form 4 filing, indicating a routine transaction to cover tax obligations. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. This particular filing indicates a sale of shares to cover tax obligations, which is a common practice.
Stakeholder Impact
- The sale of shares by a company executive can sometimes be perceived negatively by shareholders, but in this case, it's a routine transaction to cover tax obligations and is unlikely to have a significant impact.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transaction: Sale of 12,657 shares of common stock. |
| 03/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.